EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice

Mark Rusznak, Daniela Sierra-Hernandez, Catherine Dupuy, Shinji Toki, Ashley Y Wu, Uttam Rao, Masako Abney, Jian Zhang, Qianni Hu, Christian M Warren, Daniel J Drucker, Kevin D Niswender und 6 weitere

The Journal of Immunology · 2026

DOI: 10.1093/jimmun/vkaf251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Mark Rusznak und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United State…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Glucagon-Like Peptide-1 Receptor, Graft Rejection. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graft failure (GF) following hematopoietic stem cell transplantation (HSCT) remains a major complication particularly in the setting of human leukocyte antigen (HLA)-mismatched grafts where residual host lymphocytes can drive immune-mediated rejection. While strategies to mitigate GF have been explored, such as intensified conditioning or donor T cell supplementation, these approaches carry significant risks, including increased toxicity and graft-versus-host disease (GVHD). Recent studies have highlighted the glucagon-like peptide-1 receptor (GLP1R) as a critical regulator of immune homeostasis, yet its role in HSC engraftment remains unexplored. Here, we demonstrated that GLP1R deficiency in recipient mice leads to a profound increase in GF following MHC-mismatched allogeneic HSCT. Although GLP1R knockout (GLP1RKO) and wild-type (WT) mice exhibited comparable survival and engraftment following syngeneic or minor antigen-mismatched transplants, GLP1RKO mice undergoing MHC-mismatched HSCT experienced significantly greater weight loss, earlier mortality, and reduced donor chimerism. Histologic and cytokine analyses confirmed that this phenotype is not driven by GVHD, but rather by early graft rejection. Depletion of CD90+ recipient T cells prior to transplantation rescued engraftment in GLP1RKO mice, further supporting a model in which GLP1R signaling restrains host lymphocyte-mediated graft rejection. These findings identify GLP1R as a novel regulator of allogeneic HSC engraftment and suggest that GLP1R agonists, widely used for metabolic disorders, may have therapeutic potential in preventing HSC graft rejection. Given the lack of targeted interventions for HSC graft rejection, further studies are warranted to investigate GLP1R-directed therapies in the context of allogeneic HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationGlucagon-Like Peptide-1 ReceptorGraft RejectionAnimalsMiceMice, KnockoutSignal TransductionGraft vs Host DiseaseMice, Inbred C57BLTransplantation, Homologous

Stichwörter der Autor:innen

GFGLP1RHSCTrejection

Substanzen

Glucagon-Like Peptide-1 ReceptorGlp1r protein, mouse

Autor:innen und Institutionen

  • Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
  • United States Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, United States.
  • Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
  • Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.

Förderung

  • NIAID NIH HHS
  • United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service
  • NIH HHS
  • NCI NIH HHS
  • BLRD VA
  • National Institutes of Health

Zitieren

APA

Rusznak, M., Sierra-Hernandez, D., Dupuy, C., Toki, S., Wu, A. Y., Rao, U., Abney, M., Zhang, J., Hu, Q., Warren, C. M., Drucker, D. J., Niswender, K. D., Engelhardt, B., Kim, T. K., Gibson-Corley, K. N., Cahill, K. N., Cooke, K. R., & Peebles, R. S. (2026). Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf251

Vancouver

Rusznak M, Sierra-Hernandez D, Dupuy C, Toki S, Wu AY, Rao U, et al. Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkaf251

BibTeX
@article{Rusznak2026,
  author = {Rusznak, Mark and Sierra-Hernandez, Daniela and Dupuy, Catherine and Toki, Shinji and Wu, Ashley Y and Rao, Uttam and Abney, Masako and Zhang, Jian and Hu, Qianni and Warren, Christian M and Drucker, Daniel J and Niswender, Kevin D and Engelhardt, Brian and Kim, Tae Kon and Gibson-Corley, Katherine N and Cahill, Katherine N and Cooke, Kenneth R and Peebles, R Stokes},
  title = {Glucagon-like peptide-1 receptor signaling deficiency exacerbates hematopoietic stem cell graft rejection in mice},
  journal = {The Journal of Immunology},
  year = {2026},
  doi = {10.1093/jimmun/vkaf251}
}
Kostenlos starten →